海南医科大学学报

参考文献

1 Campana D.Minimal residual disease studies in acuteleukemia[J].Am J Clin Pathol,2004,122(1):47-57.

2 Pui CH,Campana D.New definition of remission inchildhood acute lymphoblastic leukemia[J].Leukemia,2000,14(5):783-785.

3 San Miguel J F,Vidriales M B,Lopez-Berges C,et al.Early immunophenotypical evaluation of minimal residualdisease in acute myeloid leukemia identifies differentpatient risk groups and may contribute to postinductiontreatment stratification[J].Blood,2001,98(6):1746-1751.

4 Van Dongen J J,Seriu T,Panzer-Grumayer E R,et al.Prognostic value of minimal residual disease in acutelymphoblastic leukemia in childhood[J].Lancet,1998,352(9142):1731-1738.

5 Tobal K,Newton J,Macheta M,et al.Molecular quanti-tation of minimal residual disease in acute myeloidleukemia with t(8;21)can identify patients in durable re-mission and predict clinical relapse[J].Blood,2000,95(3):815-819.

6 Coustan-Smith E,Sancho J,Hancock M L,et al.Clini-cal importance of minimal residual disease in childhoodacute lymphoblastic leukemia[J].Blood,2000,96(8):2691-2696.

7 Radich J P,Gooley T,Bryant E,et al.The significanceofbcr-abl molecular detection in chronic myeloid leukemiapatients l“ate”18 months or more after transplantation[J].Blood,2001,98(6):1701-1707.

8 Sramkova L,Muzikova K,Fronkova E,et al.Detectableminimal residual disease before allogeneic hematopoieticstem cell transplantation predicts extremely poor prognosisin children with acute lymphoblastic leukemia[J].PediatrBlood Cancer,2006,6(2):13.

9 Landstrom AP,Tefferi A.Fluorescent in situ hybridizstionin the diagnosis,prognosis,and treatment monitoring ofchronic myeloid leukemia[J].Leuk Lymphoma,2006,47(3):397-402.

10 Haferlach T,Kern W,Schnittger S,et al.Modern diag-nostics in acute leukemias[J].Crit Rew Oncol Hematol,2005,56(2):223-234.

11 Mancini M,Cedrone M,Diverio D,et al.Use of dual-color interphase FISH for the detection of inv(16)in acutemyeloid leukemia at diagnosis,relapse and during follow-up:a study of 23 patients[J].Leukemia,2000,14(3):364-368.

12 Radich J P.The use of PCR technology for detecting min-ima residual disease in patients with leukemia[J].Rev Im-munogene,1999,1(2):265-278.

13 Cassinat B,Zassadowski F,Balitrand N,et al.Quantita-tion of minimal residual disease in acute promyelocyticleukemia patients with t(15;17)translocation using real-time RT-PCR[J].Leukemia,2000,14(2):324-328.

14 Picard C,Silvy M,Gabert J.Overview of real-time RT-PCR strategies for quantification of gene rearrangements inthe myelois malignancies[J].Methods Mol Med,2006,125:27-68.

15 Malec M,Bjorklund E,Soderhall S,et al.Flow cytome-try and allele-specific oligonucleotide PCR are equally ef-fective in detection of minimal residual disease in ALL[J].Leukemia,2001,15(5):716-727.

16 Van der Velden V H,Jacobs D C,Wijkhuijs A J,et al.Minimal residual disease levels in bone marrow andperipheral blood are comparable in children with T cellacute lymphoblastic leukemis(ALL),but not inprecursor-B-ALL[J].Leukemia,2002,16(8):1432-1436.